Hyperliquid Labs CEO Jeff Yan outlined the company's goal to bring its blockchain-based perpetual contracts trading platform to the US market. The platform operates 24/7 and gained attention after traders used it to trade crude oil during the Iran war outbreak. Currently operating outside the US, Hyperliquid is working on meeting regulatory requirements for legal compliance in the US. President Trump mentioned that CFTC Chair Michael S. Selig is developing a compliant route for Hyperliquid's US entry.
Jeff Yan's Hyperliquid platform aims to enter the US market with blockchain-based perpetual contracts. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 15, 2026 21:16 WIB: out of 50 major cryptocurrencies, only 6 rose while 43 fell. Notable movers include Filecoin (FIL) at Rp18.369 with a 1-day change of -6.83%, Algorand (ALGO) at Rp1.975 with -6.13%, and Compound (COMP) at Rp386.709 with -5.77%.
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
TDG Gold Corp. has agreed to sell a 51% interest in its Aurora West property to Freeport-McMoRan for C$110 million in cash. Freeport also has an option to increase its ownership to 75% or 100% by funding an additional C$80 million in exploration and ...
Union Station Homeless Services is requesting community help to donate 627 frozen turkeys for its annual Dinner in the Park event, aiming to serve 6,000 Thanksgiving meals. The turkey drive will be held on November 16-17 in Pasadena, California. Dona...
Timeplast, a materials company with over 9,000 customers, has launched a Regulation A+ offering open to the public to license its patented water-soluble plastic technology. This plastic dissolves in water after a programmed period, reducing plastic w...
DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...
